Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Valsartan dispersible tablet and preparation method thereof

A technology for valsartan and dispersible tablets, applied in the field of valsartan dispersible tablets and preparation thereof, can solve the problems of slow onset of action, low bioavailability and the like, and achieve the effects of convenient administration, high bioavailability and improved curative effect

Active Publication Date: 2010-09-15
HAINAN HUALON PHARM
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The present invention just aims to solve the shortcomings of the existing valsartan agents, such as slow onset of action and low bioavailability, to improve the curative effect and reduce side effects, and to invent valsartan dispersible tablets and its preparation method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] 1000 tablets dosage

[0062] Valsartan 80g

[0063] Mannitol 50g

[0064] Starch 30g

[0065] Microcrystalline Cellulose 30g

[0066] Croscarmellose Sodium 10g

[0067] Silica 4g

[0068] Magnesium Stearate 2g

[0069] Apple Powder Flavor 1g

[0070] Sodium Lauryl Sulfate 0.3g

[0071] 1% hypromellose aqueous solution 75ml

[0072] Preparation Process:

[0073] Valsartan is passed through a 120 mesh sieve; microcrystalline cellulose and starch are passed through a 100 mesh sieve; valsartan, mannitol, starch and microcrystalline cellulose are accurately weighed according to the prescription quantity, mixed homogeneously, and binder (dodecane Sodium base sulfate is added to the binder) and mixed to make soft materials, and granulated with 18 mesh sieves; the granules are dried at 50°C for 4-6 hours; after the granules are dried, add silicon dioxide, cross-linked sodium carboxymethyl cellulose, Apple powder flavor and magnesium stearate...

Embodiment 2

[0075] 1000 tablets dosage

[0076] Valsartan 80g

[0077] Mannitol 50g

[0078] Starch 30g

[0079] Microcrystalline Cellulose 30g

[0080] Croscarmellose Sodium 10g

[0081] Silica 4g

[0082] Magnesium Stearate 2g

[0083] Apple Powder Flavor 1g

[0084] Sodium Lauryl Sulfate 0.3g

[0085] 1% hypromellose aqueous solution 75ml

[0086] Preparation Process:

[0087] Valsartan is passed through a 120 mesh sieve; microcrystalline cellulose and starch are passed through a 100 mesh sieve; valsartan, mannitol, starch and microcrystalline cellulose are accurately weighed according to the prescription quantity, mixed homogeneously, and binder (dodecane Sodium base sulfate is added to the binder) mixed to make soft material, and granulated with 18 mesh sieve; the granules are dried at 35°C for 4-6 hours; after the granules are dried, add silicon dioxide, cross-linked sodium carboxymethyl cellulose, Apple powder flavor and magnesium stearate are mix...

Embodiment 3

[0089] 1000 tablets dosage

[0090] Valsartan 80g

[0091] Mannitol 50g

[0092] Starch 28g

[0093] Microcrystalline Cellulose 35g

[0094] Crospovidone 8g

[0095] Silica 4g

[0096] Magnesium Stearate 2g

[0097] Apple Powder Flavor 1g

[0098] Sodium Lauryl Sulfate 0.3g

[0099] 1% hypromellose aqueous solution 75ml

[0100] Preparation Process:

[0101] Valsartan is passed through a 120 mesh sieve; microcrystalline cellulose and starch are passed through a 100 mesh sieve; valsartan, mannitol, starch and microcrystalline cellulose are accurately weighed according to the prescription quantity, mixed homogeneously, and binder (dodecane Sodium sulfate is added to the binder) and mixed to make a soft material, granulated with an 18-mesh sieve; the granules are dried at 50°C for 4-6 hours; after the granules are dried, add silicon dioxide, crospovidone, and apple powder essence Mix with magnesium stearate, granulate through a 20-mesh sieve; table...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides valsartan dispersible tablets and a process for preparation. The tablets contain an effective quantity of valsartan and medicinal findings which further contains disintegration agent, deflocculating agent, cementing agent, lubricating agent, flow assisting agent, and surface active agent, wherein the dosage of the valsartan is 100 parts, disintegration agent 2-50 parts, deflocculating agent 10-150 parts, cementing agent 2-25 parts, lubricating agent 0.5-20 parts, flow assisting agent 0.2-10 parts and surface active agent 0.1-2.5 parts. The invention provides the preparation process as well. In comparison with other preparation, the valsartan dispersible tablets have the advantages of excellent dispersing state, short disintegration time, fast speed of dissolving outof the drug, convenient taking medicine, low cost, convenient carrying and transporting, steady property and needs no special equipment and the like.

Description

technical field [0001] The invention belongs to the technical field of medicines, in particular to a valsartan dispersible tablet and a preparation method thereof. Background technique [0002] Angiotensin II receptor antagonists are a new class of antihypertensive drugs that have been on the market since 1996. Because of their good tolerance and definite blood pressure advantages, they have been widely used in clinical practice at home and abroad. Among them, valsartan is the second oral effective, potent and specific angiotensin II receptor antagonist successfully developed. [0003] The active hormone of the renin-angiotensin-aldosterone system is angiotensin II, which can be converted from angiotensin I under the action of ACE. Angiotensin II can bind to special receptors on cell membranes of various tissues, and it has a wide range of physiological functions, especially directly or indirectly involved in the regulation of blood pressure. As a potent vasoconstrictor, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/41A61K9/20A61K47/40A61K47/38A61P9/12
Inventor 陈益智
Owner HAINAN HUALON PHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com